New two-year data show 39 percent patients treated with CAR T remain in remission

A new article shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta® (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive.

from Latest Science News -- ScienceDaily https://ift.tt/2RqYN4s

Comments

Popular posts from this blog

Jared Leto Was Responsible for the "We Live in a Society" Line in the 'Zack Snyder's Justice League' Trailer - /FILM

How to keep Amazon, Apple, and Google from listening to your Alexa, Siri, and Assistant recordings - TechHive

Exclusive: IAEA found uranium traces at Iran 'atomic warehouse' - diplomats - Reuters